BioClinica, a provider of clinical trial management solutions worldwide, announced that, along with C.R. Bard, it has won Microsoft Corporation's prestigious Life Sciences Innovation Award. The award honors companies that utilize Microsoft solutions in the realization of business and information technology benefits, and it is presented at the Drug Information Association's (NYSEARCA:DIA) 48th Annual Meeting in Philadelphia. BioClinica was given the award for its success in revolutionizing medicine development by helping clients usher therapeutic innovations into the market quicker, fight serious ailments, improve healthcare, and enhance people's quality of life.
"Now more than ever, the life sciences industry is faced with many challenges including cutting costs and bringing new drugs and therapies to market faster," said Andrea McGonigle, national managing director, Life Sciences, Microsoft Corporation. "We are impressed with how the winners demonstrate sustainable impacts through technology, and are proud that Microsoft's software plays an important role in enabling these achievements in life sciences."
Specifically, BioClinica was acknowledged for the "Monitor Visit Report" capability of its OnPoint Clinical Trial Management System, developed for C.R. Bard. The presence of this capability makes it much easier for clinical site monitors to record crucial study information. The synchronization of local Word documents through SharePoint transforms the data into a connected list, which is then transferred and updated within OnPoint CTMS. This automated synchronization gives site monitors the power to complete forms from any location, always benefiting from maximum "local quality" intelligence, and will result in time savings on the magnitude of thousands of hours, while significantly reducing trial costs.
BioClinica and C.R. Bard were chosen for this award by a panel of industry experts from a collection of life sciences corporations in the pharmaceutical, biotechnology, and medical device industries that are creatively applying technology to develop therapeutic innovations.
"We are honored to have C.R. Bard and BioClinica receive this award in recognition of our partnership to bring new innovations to market. The power of being able to run a clinical trial from one's Microsoft Outlook client is extremely powerful as visit reports, open action items, clinical documents and monitoring visits are available everywhere, anytime. The moment you connect to a network everything is instantly updated, something which no other CTMS or clinical suite of products has the power to do," said Peter Benton, President, eClinical Division of BioClinica.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net